PharmaCyte Biotech Receives the 2017 “Pipelines of Promise” Award from BIO International
April 19 2017 - 09:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that it has received
the 2017 Buzz of BIO “Pipelines of Promise” award ahead of the 2017
BIO International Convention. Each year BIO International opens
voting for its Buzz of BIO award in two categories, “Pipelines of
Promise” and “Technologies of Tomorrow.” The winners are announced
ahead of BIO International’s annual convention.
As the winner of the “Pipelines of Promise”
award, PharmaCyte will have an opportunity to give a company
presentation in the BIO Business Forum in front of industry leaders
at the 2017 BIO International Convention, which is being held this
year at the San Diego Convention Center in San Diego, California.
Also, obtaining the award provides PharmaCyte with access to global
biotech and pharma leaders through the BIO One-on-One Partnering™
system, exposure to industry thought-leaders with over 1,500
education sessions and unparalleled networking opportunities with
16,000+ industry leaders from 76 countries. The BIO One-on-One
Partnering™ system is the most efficient way to do business in the
biotech and pharma industry without traveling all over the world.
BIO’s system makes it easy to search for and identify potential
partners and request meetings with prospective biotech investors
and senior business development executives.
The BIO International Convention attracts 16,000
biotechnology and pharma leaders who come together for one week of
intensive networking to discover new opportunities and promising
partnerships. The Convention brings together a wide spectrum of
life science and application areas, including drug discovery,
biomanufacturing, genomics, biofuels, nanotechnology and cell
therapy.
The 2017 BIO International Convention is the
world’s largest biotechnology gathering with tens of thousands of
people expected to attend this year’s Convention. It features 1,800
exhibitors and 55 regional and international pavilions, with 8
specialized product focus zones. The BIO International Convention
allows companies like PharmaCyte the opportunity to interact with
influential decision makers and high-level executives that come to
the Convention to discover new therapies in the biotechnology
sector, evaluate emerging technologies and form new
partnerships.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company developing therapies for cancer and diabetes
based upon a proprietary cellulose-based live cell encapsulation
technology known as “Cell-in-a-Box®.” This technology will be used
as a platform upon which therapies for several types of cancer and
diabetes are being developed. PharmaCyte’s therapy for cancer
involves encapsulating genetically engineered human cells that
convert an inactive chemotherapy drug into its active or
“cancer-killing” form. These encapsulated cells are implanted as
close to the patient’s cancerous tumor as possible. Once implanted,
a chemotherapy drug that is normally activated in the liver
(ifosfamide) is given intravenously at one-third the normal dose.
The ifosfamide is carried by the circulatory system to where the
encapsulated cells have been implanted. When the ifosfamide comes
in contact with the encapsulated cells they act as an artificial
liver and activate the chemotherapy drug at the source of the
cancer. This “targeted chemotherapy” has proven effective and safe
to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology. Once the encapsulated cells are
implanted in a diabetic patient they will function as a
“bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release contains forward-looking
statements, which are generally statements that are not historical
facts. Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements because of the impact of several risk
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
More information about PharmaCyte Biotech can be found at
www.PharmaCyte.com. It can also be obtained by contacting Investor
Relations.
Contact:
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com